Final Remarks and Closing: Biomarker-Driven Management in NSCLC

In closing remarks, Dr. Singhi and Dr. Jani share key takeaway on biomarker-driven management in NSCLC. Dr. Jani emphasizes that the most important step is performing NGS testing, both tissue and liquid biopsy, at diagnosis. He stresses that whenever progression occurs, both modalities should be used concurrently: tissue biopsy when feasible, but liquid biopsy should never be skipped, as it can reveal newer alterations that tissue alone may miss. He specifically highlights ctRNA as a valuable complement, noting that RNA-based testing provides additional information about fusions and other alteration data. Looking ahead, Dr. Jani anticipates that liquid biopsy will play a growing role in treatment selection, therapeutic monitoring, and MRD testing.

Dr. Singhi adds that comprehensive biomarker testing is essential not only for established targets but also for emerging biomarkers that may qualify patients for clinical trials. He underscores the importance of understanding the full biology of each patient's tumor, offering a memorable takeaway: clinicians should be "treating their lung cancer, not just lung cancer."

Thank you for watching this OncLive series on Optimizing Biomarker-Driven Management in Non-Small Cell Lung Cancer. We appreciate your commitment to advancing precision medicine for NSCLC. Please subscribe to our newsletter for updates on upcoming episodes and new data.